In this issue of the AJNR, Edwards and colleagues (page 1682) describe their experiences
with the use of intra-arterial thrombolytic therapy for the treatment of patients with acute …

Stroke affects more than 700,000 people each year in the United States and is the third
leading cause of death behind heart disease and cancer. It is the leading cause of health …

Background and Purpose—The National Institutes of Health (NIH) estimates that stroke
costs now exceed $45 billion per year. Stroke is the third leading cause of death and one of …

Acute ischemic stroke is a heterogeneous disease process that defies simple definition. It
might be likened to a Greek drama, too frequently a tragedy, wherein the dramatis personae …

Recent advances in techniques of intracranial catheterization have made it possible to
deliver thrombolytic agents intraarterially directly into the thrombus. Experimental studies …

BACKGROUND AND PURPOSE: Advances in thrombolytic therapy, brain imaging, and
neurointerventional techniques provide new therapeutic options for acute stroke. Intra …

BACKGROUND AND PURPOSE: Since the approval of intravenous tissue plasminogen
activator for acute ischemic stroke, great interest has been generated in cerebral fibrinolysis …

Several thrombolytic agents for the treatment of acute ischaemic stroke have been
examined; however, to date, only the iv administration of recombinant tissue plasminogen …

OBJECTIVE: To determine the feasibility of combined intravenous and intra-arterial
thrombolytic therapy for acute ischemic strokes and to evaluate its associated risks, using …

Stroke is a common cause of death and disability in industrialized nations. Technical
advances and the increased availability of noninvasive brain imaging techniques have …